Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1999, p. 1234-1241, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Selective Effect of
2',6'-Dihydroxy-4'-Methoxychalcone Isolated from Piper
aduncum on Leishmania amazonensis
Eduardo Caio
Torres-Santos,1
Davyson Lima
Moreira,2
Maria
Auxiliadora C.
Kaplan,2
Maria
Nazareth
Meirelles,3 and
Bartira
Rossi-Bergmann1,*
Instituto de Biofisica Carlos Chagas
Filho1 and Núcleo de Pesquisa de
Produtos Naturais,2 Universidade Federal do Rio
de Janeiro, and Laboratório de Ultraestrutura Celular,
Instituto Oswaldo Cruz, FIOCRUZ,3 Rio de
Janeiro, Brazil
Received 16 July 1998/Returned for modification 30 September
1998/Accepted 8 March 1999
 |
ABSTRACT |
2',6'-Dihydroxy-4'-methoxychalcone (DMC) was purified from the
dichloromethane extract of Piper aduncum inflorescences.
DMC showed significant activity in vitro against promastigotes and intracellular amastigotes of Leishmania amazonensis, with
50% effective doses of 0.5 and 24 µg/ml, respectively. Its
inhibitory effect on amastigotes is apparently a direct effect on the
parasites and is not due to activation of the nitrogen oxidative
metabolism of macrophages, since the production of nitric oxide by both
unstimulated and recombinant gamma interferon-stimulated macrophages
was decreased rather than increased with DMC. The phagocytic activity
of macrophages was functioning normally even with DMC concentrations as
high as 80 µg/ml, as seen by electron microscopy and by the uptake of
fluorescein isothiocyanate-labeled beads. Ultrastructural studies also
showed that in the presence of DMC the mitochondria of promastigotes were enlarged and disorganized. Despite destruction of intracellular amastigotes, no disarrangement of macrophage organelles were observed, even at 80 µg of DMC/ml. These observations suggest that DMC is selectively toxic to the parasites. Its simple structure may well enable it to serve as a new lead compound for the synthesis of novel
antileishmanial drugs.
 |
INTRODUCTION |
Leishmaniasis is a disfiguring and
sometimes fatal protozoan disease, affecting more than 12 million
people worldwide (4), for which there is still no safe
vaccine (15, 16). Recently, a dramatic increase in the rate
of Leishmania infections in human immunodeficiency virus
patients (1, 2), together with the development of drug
resistance by the parasites (5), has worsened this problem.
Despite the tremendous progress made in the understanding of the
biochemistry and molecular biology of the parasite, the first-choice
treatment for the several forms of leishmaniasis still relies on daily
intramuscular injections of pentavalent antimonials developed more than
50 years ago (9). Pentavalent antimonials are potentially
toxic and often ineffective, and the second-choice drugs, such as
amphotericin B and pentamidine, may be even more toxic (17,
30). Therefore, the search for novel, effective, and safe
therapeutic compounds has become a priority.
Plants still provide unparalleled chemical diversity and bioactivity
(34), which has led to the development of hundreds of
pharmaceutical drugs. Indeed, the majority of drugs used clinically for
the treatment of infectious agents are derived from natural products.
The antimalarial agents quinine, chloroquine, and artemisinin, and the
antiamoebic agent emetin, are good examples of successful plant-derived
drugs (8, 21). For leishmaniasis, various plant-derived compounds with activity against the parasites have been described (reviewed in reference 19), although none so far has
been developed and approved for clinical use, perhaps due to toxicity
for mammalian systems. As part of a program where antileishmanial
compounds are sought in a great variety of Brazilian plants preselected according to their chemical composition, we describe here the selective
effects of an active chalcone purified from Piper aduncum (Piperaceae) against Leishmania amazonensis, a causative
agent of cutaneous leishmaniasis.
 |
MATERIALS AND METHODS |
Plant extraction and purification of DMC.
P. aduncum
was collected in the outskirts of Rio de Janeiro State, Brazil, during
the summer. The inflorescences (150 g) were dried, powdered, and then
submitted to successive extractions with hexane, dichloromethane, and
methanol at room temperature. Each extract was evaporated to dryness
under reduced pressure before antipromastigote activity-guided
fractionation (see below). 2',6'-Dihydroxy-4'-methoxychalcone (DMC) was
purified as described previously (27). Briefly, the
dichloromethane extract (7 g) was chromatographed on a silica gel
column by using mixtures of hexane-ethyl acetate and ethyl
acetate-methanol, yielding 90 mg of a pure substance, identified by gas
chromatography-mass spectrometry and nuclear magnetic resonance as DMC
(Fig. 1).
Mice.
BALB/c mice originally purchased from Jackson
Laboratory (Bar Harbor, Maine) were bred and maintained at our own
facilities. Male mice were used at 8 to 10 weeks of age.
Parasites.
The L. amazonensis isolate LV/79
(MPRO/BR/72/M 1841) was used. The parasites were routinely isolated
from mouse lesions and maintained as promastigotes at 26°C in
Dulbecco-modified minimum essential medium (DMEM; Sigma Chemical Co.,
St. Louis, Mo.) containing 10% heat-inactivated fetal calf serum
(HIFCS; Microbiológica, Rio de Janeiro, Brazil), 100 µg of
streptomycin/ml, and 100 U of penicillin/ml (referred to below as
complete medium). Subcultures were made in the late-log phase of
growth, and parasites were used no later than at the fourth passage.
Antipromastigote activity.
The inhibition of promastigote
growth in vitro was assessed by a modification of the method described
by Yang and Liew (38). Briefly, promastigotes were incubated
at 26°C in Schneider Drosophila medium (Gibco, Paisley, United
Kingdom) plus 5% HIFCS in the presence of various concentrations of
the dichloromethane extract, DMC, or medium alone in 96-well
flat-bottom microtiter plates (Nunc, Roskilde, Denmark). After 48 h, 1 µCi of [3H]thymidine (Sigma Chemical Co.) was
added to each well. Parasites were harvested 6 h later with a dot
blot apparatus as described previously (32), and
[3H]thymidine incorporation was measured in a
-scintillation counter. All cultures were performed in triplicate,
and the results were expressed as percent inhibition in relation to
controls cultured in medium alone.
Antiamastigote activity.
Resident macrophages were harvested
from the peritoneal cavities of normal BALB/c mice in ice-cold DMEM.
The cells were plated at 2 × 106/ml (0.4 ml/well) in
Lab-Tek 8-chamber slides (Nunc, Naperville, Ill.) and incubated at
37°C under an atmosphere of 4% CO2 for 1 h.
Nonadherent cells were removed by washing with prewarmed phosphate-buffered saline (PBS). Stationary-phase L. amazonensis promastigotes were added at a 4:1 parasite/macrophage
ratio, and the cultures were incubated for a further 4 h. The cell
monolayers were washed three times with prewarmed PBS to remove free
parasites, and 0.4 ml of DMC in complete medium at different
concentrations was added in duplicate for a further 48 h. The
cultures were then fixed with absolute methanol, stained with Giemsa
stain, and examined under light microscopy. The number of intracellular
amastigotes was determined by counting at least 100 macrophages per
sample, and the results were expressed as percent inhibition in
relation to controls without DMC. The 50% effective dose
(ED50) was determined by logarithm regression analysis.
Phagocytic activity.
Resident mouse peritoneal macrophages
were harvested as described above and plated in 24-well tissue culture
plates (Nunc) at 106/well. After removal of nonadherent
cells, 0.5 ml of DMC was added at various concentrations. After 48 h of incubation at 37°C and 5% CO2, the cultures were
washed once with prewarmed PBS, and 5 × 107
fluorescein isothiocyanate (FITC)-labeled latex beads (diameter, 1 µm; Polysciences, Warrington, Pa.) were added for a further 4 h.
At the end of the incubation time, the cells were washed four times
with prewarmed PBS to remove free beads and lysed by two cycles of
freeze-thawing in distilled water, and the fluorescence in the lysate
was measured by plate fluorometry (Fluoroskan II; Labsystems Oy,
Helsinki, Finland). Negative controls were macrophages fixed with 1%
formalin prior to addition of the beads.
Nitric oxide production.
Resident mouse peritoneal
macrophages were plated and incubated at 4 × 105/well
in 96-well flat-bottom plates with DMC at several concentrations in the
presence or absence of 10 U of murine recombinant gamma interferon
(rIFN-
)/ml. After 48 h, NO production was measured by assessing
the nitrite content of culture supernatants by the method described by
Ding et al. (12). Briefly, 100 µl of fresh Griess reagent
[1% sulfanilamide p-aminobenzene sulfonamide, 5% H3PO4, 0.1%
n-(1-naphthyl)ethylenediamine dihydrochloride; Sigma] was
added to equal volumes of culture supernatants. After 10 min of
incubation at room temperature, the optical density at 570 nm was
measured. The nitrite concentration was determined by using NaNO2 diluted in DMEM as the standard and DMEM plus Griess
reagent alone as the blank. Addition of DMC did not alter the blank values.
Ultrastructural studies.
Electron microscopy studies were
carried out to examine the effect of DMC on the ultrastructures of both
promastigote and amastigote forms. For promastigotes, 5-ml suspensions
of 106 parasites/ml of complete medium were incubated for
48 h at 26°C in the presence or absence of 50 µg of DMC/ml in
25-cm2 tissue culture flasks (Nunc). The cells were then
washed with PBS, centrifuged, and fixed with 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer (pH 7.2) for 1 h. For intracellular
amastigotes, 5-ml suspensions of 2 × 106 resident
peritoneal exudate cells/ml were plated in 25-cm2 tissue
culture flasks and macrophages were infected as described above. The
infected cells were incubated with 40 or 80 µg of DMC/ml or with
complete medium alone for 48 h. The macrophages were washed twice
with prewarmed PBS, fixed as for promastigotes, and collected by gentle
scraping. Both promastigotes and infected macrophages were postfixed
with 1% OsO4 and 0.8% potassium ferricyanide, then washed
with PBS, included in agar, dehydrated with acetone, and embedded in
Epon. Fine sections were made with an ultramicrotome LKB Ultratome V,
stained with uranyl acetate and lead citrate, and examined in a Zeiss
EM10C electron microscope.
 |
RESULTS |
Inhibition of parasite growth.
The dichloromethane extract
from P. aduncum inflorescences actively decreased the
viability of promastigotes of L. amazonensis in vitro, as
monitored by reduction in DNA synthesis following a 48-h parasite
culture in the presence of the extract. The crude extract inhibited
promastigote growth with an ED50 of 2.2 µg/ml (Fig.
2). Preliminary experiments demonstrated
that inflorescences were superior to leaves and stems and that
dichloromethane was better than hexane and methanol in extracting the
active substance(s). Antipromastigote activity-guided fractionation led
to the purification of DMC, which showed an ED50 of 0.5 µg/ml (Fig. 2). Purified DMC was also tested on intracellular
amastigotes, and three independent experiments showed that whereas the
percentage of infected macrophages was reduced by half at 40 µg of
DMC/ml (Fig. 3A), the parasite load was
reduced by half at 24 µg/ml (the ED50) (Fig. 3B). We observed no apparent toxic effect of DMC on macrophages by light microscopy, such as rounding or detachment from the substrate, even at
100 µg/ml.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of the crude dichloromethane extract of P. aduncum and the isolated DMC against promastigotes of L. amazonensis. Promastigotes were cultured for 48 h in the
presence of the indicated concentrations of dichloromethane extract
( ) or DMC ( ). [3H]thymidine incorporation for
controls in medium alone, taken as 100%, was 11,700 cpm. Data are
means ± standard deviations (SD).
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of DMC against intracellular amastigotes.
Macrophages were infected with L. amazonensis and cultivated
for 48 h in the presence of the indicated concentrations of DMC.
(A) Percentage of infected macrophages. (B) Parasite load (number of
amastigotes/macrophage) as a percentage of that in controls, taken as
100%. Controls averaged 12 amastigotes/macrophage. Each experimental
point is the mean from two independent cultures ± SD.
|
|
Effect of DMC on macrophage phagocytosis.
To assess whether
DMC affects macrophage phagocytic activity, and hence viability,
macrophage monolayers were incubated for 48 h in the presence of
increasing concentrations of DMC and then were allowed to phagocytose
FITC-labeled latex beads. Figure 4 shows
that the phagocytic activity in the presence of higher (80-µg/ml) concentrations of DMC was the same as that of untreated cells. These
results, together with the observations that DMC at 100 µg/ml does
not affect the proliferative response of lymph node cells to
concanavalin A (measured by the incorporation of
[3H]thymidine) or the viability of lymph node cells or
murine mastocytoma cells (as measured by trypan blue dye exclusion and
51Cr release assays, respectively [data not shown]),
indicate that DMC is selectively toxic to the parasites but not to
mammalian cells.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of DMC on the phagocytic activity of macrophages.
Macrophages were preincubated for 18 h in the presence of the
indicated concentrations of DMC, washed, and then allowed to
phagocytose FITC-labeled latex beads for a further 4 h. After
washing, the fluorescence in the cell monolayers was measured. Dashed
line, background fluorescence in macrophage cultures fixed with
formalin and treated in the same way. Data are means ± SD
(n = 3).
|
|
Effect of DMC on nitric oxide production by macrophages.
To
investigate whether the apparent increase in phagocytic activity
observed in Fig. 4 reflected a generalized activation state of
macrophages that could include microbicidal mechanisms, we measured the
production of NO upon incubation with DMC. When resident macrophages
were incubated for 48 h in the presence of increasing
concentrations of DMC, a steady decrease in spontaneous NO production
was observed (Fig. 5). The capacity of
macrophages to produce NO was abolished by DMC even in the presence of
10 U of rIFN-
/ml, which by itself produced a fivefold increase in NO
synthesis, and was almost completely abrogated by the presence of 10 µg of DMC/ml (Fig. 5). These results suggest that the antiamastigote activity of DMC is not due to activation of this powerful
leishmanicidal mechanism evolved by the macrophages (12,
22-24) but may rather be due to the direct effect of DMC on the
parasites.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of DMC on the production of nitric oxide by
macrophages. Macrophages were cultivated for 48 h in the presence
of the indicated concentrations of DMC in the absence (top) or presence
(bottom) of 50 U of rIFN- /ml. The nitrite concentration in the cell
supernatants was measured with Griess reagent. Data are means ± (n = 3).
|
|
Electron microscopy studies.
To better evaluate the
subcellular changes induced by DMC on the parasites, either free
promastigotes or intracellular amastigotes were cultured for 48 h
in the presence of different concentrations of DMC and then processed
for electron microscopy. For promastigotes, treatment with 50 µg of
DMC/ml induced an increase in the size and number of electron-dense
granules (Fig. 6B) compared to those in
untreated controls (Fig. 6A). The promastigote forms displayed enlarged
and more-diffuse mitochondrion profiles with a loss of matrix and
crista patterns, indicating damage to that organelle.

View larger version (124K):
[in this window]
[in a new window]
|
FIG. 6.
Ultrastructural effects of DMC on promastigotes.
Promastigotes were incubated in medium alone (A) or with 50 µg of
DMC/ml (B) for 48 h. (A) Section showing the normal aspect of the
nucleus (n) and mitochondrion (m) containing the kinetoplast (arrow).
(B) A promastigote exhibiting several electron-dense granules (G) and a
dense mitochondrion (m) with a swollen matrix and loss of cristae.
|
|
A typical intracellular amastigote from untreated cultures is shown in
Fig.
7A, where the normal size and
electron density
of the nucleus and kinetoplast are seen. Clear changes
can be
seen when the cultures are treated with 40 µg of DMC/ml (Fig.
7B); a vacuole containing degraded parasite organelles such as
membrane-associated subpellicular microtubules and flagella was
found.
Treatment of infected macrophages with a higher concentration
of DMC
(80 µg/ml) (Fig.
8) produced greater
parasite destruction,
such that no intact parasites could be found.
Figure
8A shows
the presence of subpellicular microtubules of the
parasite membrane
and a highly electron-dense material inside the
parasitophorous
vacuole. At 80 µg of DMC/ml, most macrophages, such
as that represented
in Fig.
8B, showed well-preserved mitochondria,
abundant endoplasmic
reticulum, and vacuoles containing degraded
material, possibly
amastigotes. Plasma membrane projections are also
seen. This observation
is consistent with the enhanced phagocytic
activity demonstrated
in Fig.
4 for latex beads.

View larger version (172K):
[in this window]
[in a new window]
|
FIG. 7.
Ultrastructural effects of DMC on intracellular
amastigotes. Infected macrophages were cultured in medium alone (A) or
with 40 µg of DMC/ml (B) for 48 h. (A) A normal amastigote
nucleus (n), a kinetoplast (arrow), and a few electron-dense granules
(G) are shown. (B) Disrupted amastigote identified by subpellicular
microtubules (arrowheads) and flagellum (f) inside a vacuole of a
representative macrophage.
|
|

View larger version (162K):
[in this window]
[in a new window]
|
FIG. 8.
Electron micrograph of infected macrophage cultures
treated with 80 µg of DMC/ml. (A) Section of an infected macrophage
showing a vacuole (v) containing a large, dense material; subpellicular
microtubules (arrowheads); and debris from a disrupted amastigote. (B)
Section of a macrophage with normal mitochondrion profiles (m),
endoplasmic reticulum (ER), membrane projections (arrows), and large
vacuoles (v) containing cellular debris.
|
|
 |
DISCUSSION |
Chalcones are flavonoids present in a variety of plant species. A
range of biological effects, such as antibacterial, antitumor, antifungal (3, 29), antiviral (11), and
antiplasmodial (20) activities, have been ascribed to them.
This paper describes for the first time the activity of DMC against
both promastigote and amastigote forms of L. amazonensis.
The antileishmanial activity of a different chalcone, the licochalcone
A isolated from the roots of Glycyrrhiza spp. (Fabaceae),
has been described for Leishmania major and Leishmania
donovani (6, 7, 39). In those studies, the
ED50 against the amastigotes of both species was 4 µg/ml, a dose sixfold smaller than found here for DMC against L. amazonensis (24 µg/ml). However, the efficacies of those two
chalcones cannot be compared due to differences in experimental
protocols, and more importantly, also in drug susceptibility among
parasite species. L. amazonensis may be more refractory than
other Leishmania species to different drugs (28)
and to the toxic effects of nitric oxide (31).
Generally, the antiamastigote activity of a drug may be selective and
direct against the parasite, or it may act indirectly, by activating
macrophage microbicidal mechanisms, such as the production of NO, which
is considered the most important macrophage leishmanicidal mechanism
(14, 23, 26, 36). For instance, activation of the NO
synthase pathway is involved in the protective effect of the leaf
extract of the plant Kalanchoe pinnata against infection of
BALB/c mice with L. amazonensis (10), an effect that is reversible with NO inhibitors and that may also be responsible for the observed immunosuppressive effect of that plant
(33). In the present work, the antileishmanial effect of DMC
seems to result from direct action on the parasite rather than from
activation of NO production by the macrophages, as evidenced by its
inhibitory action on axenic promastigotes (Fig. 2 and 6B). The activity
of a drug against axenic promastigotes or axenic amastigotes is not per
se indicative of antileishmanial action, as the drug may not reach the
parasitophorous vacuole, may be metabolically converted into different
products by the macrophages (35), or may simply be
nonselectively cytotoxic. We observed by optical and by electron microscopy that effective antiamastigote concentrations of DMC (Fig. 3)
inflicted no significant damage on macrophages. The evidence for
selectivity against the parasites was reinforced by the observation that other mammalian cell types, such as murine T cells and the mastocytoma cell line P815, showed no signs of cytotoxicity with concentrations of DMC as high as 100 µg/ml (data not shown). The phagocytic function of macrophages operated normally in the presence of
DMC (Fig. 4). Plasma membrane projections were seen, indicating that
the drug maintained macrophage phagocytic activity (Fig. 8B) and
vitality at concentrations which were toxic against the parasites.
However, the capacity of macrophages to spontaneously produce NO in
culture was ablated with low concentrations of DMC (Fig. 5). The
antioxidative effect of DMC was strong enough to inhibit
IFN-
-induced NO production (Fig. 5), indicating that the
antiamastigote effect of DMC is not due to the induction of toxic
nitrogen intermediates by macrophages and may rather be direct and
selective against the parasite.
We observed that DMC strongly affects the mitochondria of promastigotes
at 50 µg/ml (Fig. 6B). Other leishmanicidal drugs, such as
paromomycin (25) and licochalcone A (7), also
affect the parasite mitochondrion. In fact, the ultrastructural
alterations induced by licochalcone A in promastigotes and amastigotes
of L. donovani were similar to those observed in this study
for DMC and L. amazonensis. However, unlike licochalcone A
(39), DMC did not affect the macrophage mitochondrion at
higher concentrations (80 µg/ml), suggesting that despite the higher
ED50 required for the leishmanicidal activity discussed
above, use of DMC may be safer for mammalian cells.
The mechanism(s) by which DMC kills leishmaniae is still unknown. Other
chalcones have been shown to inhibit glutathione reductase (40), rendering them possible candidates as inhibitors of
trypanothione reductase, the enzyme responsible for the redox balance
in trypanosomatids. Whether DMC affects parasite oxidative metabolism
is not known yet, but this possibility should be considered, since
methyl and hydroxy substituents have been shown to greatly increase the
antioxidant activity of chalcones (3). In fact, the reduced
capacity of macrophages to produce NO in the presence of DMC (Fig. 5)
may reflect the drug's effect on the nitrogen oxidative
metabolism. Another importnat chemotherapeutic target
in trypanosomatids and fungi is ergosterol synthesis, as this
sterol is the main lipid component of their membranes and mammalian
cells do not produce it (37). The possibility that DMC acts
on this pathway should also be considered, as inhibitory activity of
DMC against the fungi Candida albicans and
Cryptococcus neoformans has been reported (29).
Overall, the results of this work, besides further supporting the
antileishmanial activity of chalcones, present a compound of this group
which is nontoxic to various mammalian cell types at concentrations
that effectively kill all intracellular parasites in vitro. The wide
use of P. aduncum formulations in folk medicine for the
treatment of unrelated diseases, such as trachoma and stomachaches
(13), and for the healing of wounds (18) is
indicative that DMC may be safely used in humans. P. aduncum
grows abundantly in all regions of endemicity for leishmaniasis in
Brazil, including the Amazonia, where the access of the population to
medical care is limited and L. amazonensis infection is very
prevalent. The use of inflorescences for the preparation of DMC-rich
extracts in the treatment of leishmaniasis would not damage the
species, as would the use of the roots of Chinese
Glycyrrhiza for the extraction of licochalcone. Another
advantage of DMC is that its chemical structure is simpler than that of
licochalcone (6), which may make it a less complex model for
the synthesis of a novel antileishmanial chalcone.
 |
ACKNOWLEDGMENT |
We are indebted to Venício Féo da Veiga from the
Setor de Microscopia Eletrônica, Instituto de Microbiologia-UFRJ,
for help with the electron microscopy preparations.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Instituto de
Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21.949-900 Rio de Janeiro, RJ, Brazil. Phone: 55 (21) 260 6963. Fax: 55 (21) 2808193. E-mail: bbergman{at}ibccf.biof.ufrj.br.
 |
REFERENCES |
| 1.
|
Albrecht, H.,
I. Sobottka,
C. Emminger,
H. Jablonowski,
G. Just,
A. Stoehr,
T. Kubin,
B. Salzberger,
T. Lutz, and J. van Lunzen.
1996.
Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani.
Arch. Pathol. Lab. Med.
120:189-198[Medline].
|
| 2.
|
Alvar, J.
1994.
Leishmaniasis and AIDS co-infection: the Spanish example.
Parasitol. Today
10:160-163.
|
| 3.
|
Anto, R. J.,
K. Sukumaran,
G. Kuttan,
M. N. Rao,
V. Subbaraju, and R. Kuttan.
1995.
Anticancer and antioxidant activity of synthetic chalcones and related compounds.
Cancer Lett.
97:33-37[Medline].
|
| 4.
|
Ashford, R. W.,
P. Desjeux, and P. de Raadt.
1992.
Estimation of population at risk of infection and number of cases of leishmaniasis.
Parasitol. Today
8:104-105.
[Medline] |
| 5.
|
Berman, J. D.
1997.
Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last ten years.
Clin. Infect. Dis.
24:684-703[Medline].
|
| 6.
|
Chen, M.,
S. B. Christensen,
J. Blom,
E. Lemmich,
L. Nadelmann,
K. Fich,
T. G. Theander, and A. Kharazmi.
1993.
Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania.
Antimicrob. Agents Chemother.
37:2550-2556[Abstract/Free Full Text].
|
| 7.
|
Chen, M.,
S. B. Christensen,
T. G. Theander, and A. Kharazmi.
1994.
Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.
Antimicrob. Agents Chemother.
38:1339-1344[Abstract/Free Full Text].
|
| 8.
|
Croft, S. L.
1994.
A rationale for antiparasite drug discovery.
Parasitol. Today
10:385-386.
|
| 9.
|
Croft, S. L.,
J. A. Urbina, and R. Brun.
1997.
Chemotherapy of human leishmaniasis and trypanosomiasis, p. 245-257.
In
G. Hide, J. C. Mottram, G. H. Coombs, and P. H. Holmes (ed.), Trypanosomiasis and leishmaniasis. CAB International, London, United Kingdom.
|
| 10.
| Da Silva, S. A., G. S. S. Costa, and B. Rossi-Bergmann. The anti-leishmanial effect of
Kalanchoe is mediated by nitric oxide intermediates.
Parasitology, in press.
|
| 11.
|
Dewindt, B.,
K. van Eemeren, and K. Andries.
1994.
Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
Antivir. Res.
25:67-72[Medline].
|
| 12.
|
Ding, A. H.,
C. F. Nathan, and D. J. Stuehr.
1988.
Release of reactive nitrogen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.
J. Immunol.
141:2407-2412[Abstract].
|
| 13.
|
Duke, J. A.
1985.
Handbook of medicinal herbs.
CRC Press, New York, N.Y.
|
| 14.
|
Green, S. J.,
M. S. Meltzer,
J. R. Hibb, and C. Nacy.
1990.
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism.
J. Immunol.
144:278-283[Abstract].
|
| 15.
|
Grimaldi, G. J.
1995.
Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR).
Mem. Inst. Oswaldo Cruz
90:553-556[Medline].
|
| 16.
|
Handman, E.
1997.
Leishmania vaccines: old and new.
Parasitol. Today
13:236-238.
|
| 17.
|
Hepburn, N. C.,
I. Siddique,
A. F. Howie,
G. J. Beckett, and P. C. Hayes.
1994.
Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis.
Trans. R. Soc. Trop. Med. Hyg.
88:453-455[Medline].
|
| 18.
|
Holdsworth, D., and F. Damasc.
1986.
Medicinal plants of Morobe Province, Papua New Guinea.
Int. Guide Drug Res.
24:217.
|
| 19.
|
Iwu, M. M.,
J. E. Jackson, and B. G. Schuster.
1994.
Medicinal plants in the fight against leishmaniasis.
Parasitol. Today
10:65-68.
|
| 20.
|
Kharazmi, A.,
M. Chen,
T. G. Theander, and S. B. Christensen.
1997.
Discovery of oxygenated chalcones as novel antimalarial agents.
Ann. Trop. Med. Parasitol.
91:S91-S95.
|
| 21.
|
Kirby, G. C.
1996.
Medicinal plants and the control of protozoal disease, with particular reference to malaria.
Trans. R. Soc. Trop. Med. Hyg.
90:605-609[Medline].
|
| 22.
|
Lemesre, J.-L.,
D. Sereno,
S. Daulouede,
B. Veyret,
N. Brajon, and P. Vincendeau.
1997.
Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigote and axenically grown amastigote forms.
Exp. Parasitol.
86:56-68.
|
| 23.
|
Liew, F. Y., and F. E. G. Cox.
1991.
Nonspecific defense mechanism: the role of nitric oxide.
Immunoparasitol. Today
1991:A17-A21.
|
| 24.
|
Liew, F. Y.,
S. Millot,
C. Parkinson,
R. M. J. Palmer, and S. Moncada.
1990.
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine.
J. Immunol.
144:4794-4797[Abstract].
|
| 25.
|
Maarouf, M.,
Y. de Kouchkovsky,
S. Brown,
P. X. Petit, and M. Robert-Gero.
1997.
In vivo interference of paromomycin with mitochondrial activity of Leishmania.
Exp. Cell Res.
232:339-348[Medline].
|
| 26.
|
Mauel, J., and A. Ransijn.
1997.
Leishmania spp. Mechanisms of toxicity of nitrogen oxidation products.
Exp. Parasitol.
87:98-111[Medline].
|
| 27.
|
Moreira, D. L.,
E. F. Gimarães, and M. A. C. Kaplan.
1998.
A chromene from Piper aduncum L.
Phytochemistry
48:1075-1077.
|
| 28.
|
Neal, R. A.,
S. Allen,
N. McCoy,
P. Olliaro, and S. L. Croft.
1995.
The sensitivity of Leishmania species to aminosidine.
J. Antimicrob. Chemother.
35:577-584[Abstract/Free Full Text].
|
| 29.
|
Okunade, A. L.,
C. D. Hufford,
A. M. Clark, and D. Lentz.
1997.
Antimicrobial properties of the constituents of Piper aduncum.
Phytother. Res.
11:142-144.
|
| 30.
|
Olliaro, P. I., and D. M. Bryceson.
1993.
Practical progress and new drugs for changing patterns of leishmaniasis.
Parasitol. Today
9:323-328.
[Medline] |
| 31.
|
Romão, P. R. T.,
S. A. Antoniazi,
H. C. Lima,
A. K. Cruz, and F. Q. Cunha.
1997.
Is glutathione an important virulence factor in leishmaniasis?
Mem. Inst. Oswaldo Cruz
92(Suppl. I):219.
|
| 32.
|
Rossi-Bergmann, B., and G. Noleto.
1994.
A low-cost and efficient procedure for harvesting DNA-labeled cells using a dot-blot apparatus.
BioTechniques
17:678-680[Medline].
|
| 33.
|
Rossi-Bergmann, B.,
S. S. Costa,
M. B. S. Borges,
S. A. Da Silva,
G. Noleto,
M. L. M. Souza, and V. L. G. Moraes.
1994.
Immunosuppressive effect of the aqueous extract of Kalanchoe pinnata in mice.
Phytother. Res.
8:399-402.
|
| 34.
|
Science
1990.
Medicine from plants.
Science
247:513[Free Full Text]. (Editorial.)
|
| 35.
|
Sereno, D.,
M. Cavaleyra,
K. Zemzoumi,
S. Maquaire,
A. Ouaissi, and J. L. Lemesre.
1998.
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Antimicrob. Agents. Chemother.
42:3097-3102[Abstract/Free Full Text].
|
| 36.
|
Stenger, S.,
H. Thuring,
M. Rollinghoff, and C. Bogdan.
1994.
Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major.
J. Exp. Med.
180:783-789[Abstract/Free Full Text].
|
| 37.
|
Urbina, J. A.
1997.
Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites.
Parasitology
114:S91-S99.
|
| 38.
|
Yang, D. M., and F. Y. Liew.
1993.
Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis.
Parasitology
106:7-11.
|
| 39.
|
Zhai, L.,
J. Blom,
M. Chen,
S. B. Christensen, and A. Kharazmi.
1995.
The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria.
Antimicrob. Agents. Chemother.
39:2742-2748[Abstract].
|
| 40.
|
Zhang, K.,
E. B. Yang,
W. Y. Tang,
K. P. Wong, and P. Mack.
1997.
Inhibition of glutathione reductase by plant polyphenols.
Biochem. Pharmacol.
54:1047-1053[Medline].
|
Antimicrobial Agents and Chemotherapy, May 1999, p. 1234-1241, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Torres-Santos, E. C., Sampaio-Santos, M. I., Buckner, F. S., Yokoyama, K., Gelb, M., Urbina, J. A., Rossi-Bergmann, B.
(2009). Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. J Antimicrob Chemother
63: 469-472
[Abstract]
[Full Text]
-
Tiuman, T. S., Ueda-Nakamura, T., Garcia Cortez, D. A., Dias Filho, B. P., Morgado-Diaz, J. A., de Souza, W., Nakamura, C. V.
(2005). Antileishmanial Activity of Parthenolide, a Sesquiterpene Lactone Isolated from Tanacetum parthenium. Antimicrob. Agents Chemother.
49: 176-182
[Abstract]
[Full Text]
-
Delorenzi, J. C., Attias, M., Gattass, C. R., Andrade, M., Rezende, C., da Cunha Pinto, A., Henriques, A. T., Bou-Habib, D. C., Saraiva, E. M. B.
(2001). Antileishmanial Activity of an Indole Alkaloid from Peschiera australis. Antimicrob. Agents Chemother.
45: 1349-1354
[Abstract]
[Full Text]
-
Torres-Santos, E. C., Rodrigues, J. M. Jr., Moreira, D. L., Kaplan, M. A. C., Rossi-Bergmann, B.
(1999). Improvement of In Vitro and In Vivo Antileishmanial Activities of 2',6'-Dihydroxy-4'-Methoxychalcone by Entrapment in Poly(D,L-Lactide) Nanoparticles. Antimicrob. Agents Chemother.
43: 1776-1778
[Abstract]
[Full Text]